J. David Enloe Jr. - 18 Jan 2022 Form 4 Insider Report for Recro Pharma, Inc.

Role
Chief Executive Officer, Director
Signature
By: Ryan D. Lake, attorney- in-fact
Issuer symbol
N/A
Transactions as of
18 Jan 2022
Net transactions value
+$1,011
Form type
4
Filing time
19 Jan 2022, 15:30:29 UTC
Previous filing
17 Dec 2021
Next filing
24 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SCTL Common Stock Purchase $1,011 +602 +0.39% $1.68 154,759 18 Jan 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.